Granulocyte-Macrophage Colony-Stimulating Factor
"Granulocyte-Macrophage Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
| Descriptor ID |
D016178
|
| MeSH Number(s) |
D12.644.276.374.410.240.375 D12.776.395.240.300 D12.776.467.374.410.240.375 D23.529.374.410.240.375
|
| Concept/Terms |
Granulocyte-Macrophage Colony-Stimulating Factor- Granulocyte-Macrophage Colony-Stimulating Factor
- Granulocyte Macrophage Colony Stimulating Factor
- CSF-2
- Tumor-Cell Human GM Colony-Stimulating Factor
- Tumor Cell Human GM Colony Stimulating Factor
- GM-CSF
- Histamine-Producing Cell-Stimulating Factor
- Cell-Stimulating Factor, Histamine-Producing
- Histamine Producing Cell Stimulating Factor
- TC-GM-CSF
- Colony-Stimulating Factor, Granulocyte-Macrophage
- Colony Stimulating Factor, Granulocyte Macrophage
- CSF-GM
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte-Macrophage Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte-Macrophage Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte-Macrophage Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in Profiles.
-
Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med. 2015 Oct 20; 13:333.
-
Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec; 1274:68-76.
-
Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53.
-
GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity. 2012 Jun 29; 36(6):1031-46.
-
GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol. 2011 Dec 15; 240-241:65-73.
-
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011 Nov; 52(11):2097-104.
-
A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb; 253(2):328-35.
-
HIV-1-infected peripheral blood mononuclear cells enhance neutrophil survival and HLA-DR expression via increased production of GM-CSF: implications for HIV-1 infection. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):16-25.
-
The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. J Cell Physiol. 2010 Nov; 225(2):569-76.
-
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010 Jun; 6(6):941-9.